What is mazdutide?
Mazdutide is a synthetic lipidated peptide studied in research as a dual receptor agonist with simultaneous activity at the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It is catalogued under CAS number 2259884-03-0, with a molecular formula of C₂₀₇H₃₁₇N₄₅O₆₅ and a molecular weight of approximately 4599 g/mol. The compound is supplied as a lyophilized powder for laboratory research use and is not intended for human use.
Mazdutide belongs to the incretin-adjacent compound class — a category of synthetic peptides that engage the receptor axes involved in metabolic signaling, including GLP-1R, GIPR, and GCGR. What distinguishes mazdutide from single-target GLP-1R agonists is its glucagon receptor component: the compound is designed to engage both axes simultaneously within a single molecular scaffold. This dual-target profile is the primary reason mazdutide is studied as a distinct research compound rather than as a variant of earlier single-receptor agonists.
Within the broader landscape of incretin-class research peptides — which range from single-target GLP-1R agonists like GLP-1(S) to triple agonists like GLP-3(R) — mazdutide occupies the dual-agonist position. For an overview of how these compounds relate to one another within the metabolic research category, see The Incretin Research Compound Category in 2026.
What is mazdutide's molecular structure?
Mazdutide is a single-chain synthetic peptide with a molecular weight of approximately 4599 g/mol and the molecular formula C₂₀₇H₃₁₇N₄₅O₆₅. Like other long-acting research peptides in the incretin-adjacent class, its structure incorporates a fatty acid moiety attached to the peptide backbone — a structural modification known as lipidation. This feature is common to modern GLP-1R agonist scaffolds and is the primary structural driver of extended circulating stability in pharmacokinetic research models.
The fatty acid side chain promotes reversible binding to serum albumin in in vitro and in vivo model systems. Because albumin-bound peptide is not available for rapid renal clearance, lipidation substantially extends the pharmacokinetic half-life profile of the compound relative to unlipidated GLP-1 analogs. The extended residence time makes lipidated compounds such as mazdutide relevant for extended-duration pharmacokinetic research designs in preclinical models — though this article does not provide experimental protocols, which fall outside the scope of research compound documentation.
The research-grade material is characterized to a purity specification of 99.0% or higher by HPLC, and is supplied as a white to off-white lyophilized powder. As with all lipidated peptides, the structural integrity of the fatty acid modification is sensitive to temperature, oxidation, and moisture. The implications for handling and cold-chain requirements are addressed below.
What receptors does mazdutide target?
Published research characterizes mazdutide as a dual agonist at two class B G-protein-coupled receptors: the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Both are class B GPCRs — a family that signals primarily through adenylyl cyclase activation and intracellular cyclic AMP (cAMP) elevation. The two receptors are structurally related, share ligand-binding domain architecture, and are both expressed in tissue types relevant to metabolic signaling research.
The GLP-1 receptor is one of the most extensively characterized receptors in the incretin literature. GLP-1R is expressed on pancreatic beta cells, central nervous system regions involved in energy regulation circuitry, and a range of peripheral tissues. Its activation is studied in the context of insulin secretion pathway signaling, cAMP-mediated downstream cascades, and beta-cell function in cell culture models.
The glucagon receptor is expressed primarily in the liver, where it mediates glucagon-stimulated glycogenolysis and gluconeogenesis signaling. In research models, GCGR activation produces cAMP elevation in hepatocyte cell lines and modulates hepatic glucose output signaling in ex vivo preparations. The glucagon receptor occupies a counter-regulatory position relative to the incretin receptors in metabolic pathway research: where GLP-1R and GIPR are studied for their roles in insulin secretion pathway signaling, GCGR is studied for its role in the opposing hepatic glucose mobilization axis.
Mazdutide's dual receptor profile means that research using this compound investigates how simultaneous engagement of both axes affects downstream signaling — a question that cannot be addressed using either receptor's single-target ligand alone.
How does mazdutide's dual receptor profile compare to single-target GLP-1R agonists?
The defining difference between mazdutide and a single-target GLP-1 receptor agonist is the addition of glucagon receptor activity. A compound like GLP-1(S) engages GLP-1R exclusively; mazdutide engages GLP-1R and GCGR simultaneously. This distinction matters because it changes the interpretation of experimental results and the appropriate controls for any research model.
| Property | GLP-1R agonist (single-target) | Mazdutide (dual agonist) |
|---|---|---|
| Receptor targets | GLP-1R only | GLP-1R + GCGR |
| Relevant pathway axes | Incretin signaling | Incretin + hepatic glucagon signaling |
| Concentration-response studies | Single-receptor binding kinetics | Balanced dual-receptor activity characterization |
| Appropriate controls | GLP-1R antagonist | GLP-1R and GCGR selective antagonists |
In research design terms, a dual agonist like mazdutide requires more complex control conditions than a single-target compound. To attribute observed signaling effects to one receptor versus the other, researchers typically use receptor-selective antagonists or receptor knockout models. The relative potency of mazdutide at each of its two targets is not fixed as a ratio across all assay systems — the balance can shift depending on receptor expression levels, assay format, and concentration range — making the dual-receptor characterization an active area of pharmacological investigation.
For a broader orientation to where single, dual, and triple agonists sit in the incretin research spectrum, see The Incretin Research Compound Category in 2026.
What does published research describe about mazdutide's receptor pharmacology?
Research on mazdutide is organized around characterizing the balance and consequence of simultaneous GLP-1R and GCGR engagement. The primary pharmacological questions are: at what concentration does mazdutide activate each receptor, what is the relative potency ratio between its GLP-1R and GCGR activity, and how does that balance shift in different cell and tissue models?
Published receptor binding studies characterize mazdutide's activity at recombinant GLP-1R and GCGR, typically using cAMP accumulation as the primary functional readout — a standard approach for class B GPCR research. Concentration-response studies in GLP-1R-expressing cell lines and GCGR-expressing hepatocyte models are the standard assay formats. Selectivity profiling against related class B GPCRs, including GIPR, is also described in the research literature as part of full receptor selectivity characterization.
The structural features that drive mazdutide's dual activity have been investigated in the context of peptide engineering for class B GPCR recognition. The receptor's extracellular domain-binding and transmembrane domain-binding components are both implicated in the activation mechanism for GLP-1R and GCGR, and mazdutide's peptide backbone is designed to engage both binding sites. Research on the structural determinants of dual versus single-receptor selectivity in this compound class — including amino acid substitutions and lipid attachment position — is an active area within the GPCR peptide pharmacology literature.
All research findings on mazdutide should be interpreted within the mechanistic framing appropriate for a research compound: receptor pharmacology, signaling pathway characterization, and in vitro cell model data. Metatide does not make therapeutic claims regarding mazdutide; it is supplied for receptor pharmacology research and related laboratory investigation only.
How does mazdutide compare to other dual and triple agonists in research?
Mazdutide occupies a specific receptor profile position within the incretin-adjacent research compound category. Several other dual and triple agonist research compounds have overlapping but distinct receptor targets:
Cagrilintide targets the amylin receptor alongside GCGR rather than GLP-1R, giving it a different receptor selectivity profile than mazdutide despite a similar dual-agonist structural class.
GLP-3(R) (retatrutide) engages GLP-1R, GIPR, and GCGR simultaneously — a triple agonist profile that includes mazdutide's two targets plus the GIPR axis. Research comparing dual versus triple agonism at overlapping receptor sets uses compounds like mazdutide and GLP-3(R) as reference points.
GLP-1(S) is the corresponding single-target reference for GLP-1R research — its activity at GLP-1R without GCGR involvement makes it a useful control or comparator compound in studies examining what GCGR co-agonism adds to observed signaling.
The ability to select compounds at different positions along the receptor-target spectrum — single, dual, and triple — is central to research design in this category. Researchers characterizing how receptor combinations affect downstream signaling need reference compounds at each position.
What stability and handling considerations apply to mazdutide?
Mazdutide is stored at −20°C in its lyophilized form and should be protected from moisture, oxidation, and repeated freeze-thaw cycles. As a lipidated peptide, its primary structural vulnerability is the fatty acid modification: the bond between the lipid moiety and the peptide backbone is susceptible to hydrolysis under aqueous conditions and to oxidative degradation under poor storage conditions.
This matters for research reproducibility because a mazdutide sample with a degraded or cleaved fatty acid will have a different pharmacokinetic profile in in vivo models and different albumin-binding behavior in in vitro systems. The activity may be affected even if HPLC purity remains nominally acceptable — because lipid degradation products can co-elute with the intact compound in some chromatographic methods. Mass spectrometry confirmation is therefore the essential complement to purity testing for this compound.
Cold-chain shipping is standard for all mazdutide orders from Metatide. This article does not provide preparation or handling protocols for mazdutide; those protocols are the responsibility of the researcher, based on their experimental requirements and applicable institutional guidelines.
How does Metatide supply mazdutide?
Metatide supplies mazdutide as a research-grade compound held to a 99.0% or higher minimum purity specification by HPLC, with mass spectrometry identity confirmation included in the batch-specific Certificate of Analysis. Endotoxin testing is conducted per batch. All orders ship cold-chain packaged as standard.
Specifications, available sizes, and pricing are on the product page for Mazdutide. The full metabolic compound catalog — including GLP-1(S), GLP-3(R), and other incretin-class compounds — is available at all compounds. All material is for laboratory research use only — not for human use.
Mazdutide is a research chemical intended for laboratory and scientific research purposes only. Not for human use. It is not a drug, supplement, or food, and is not intended to diagnose, treat, cure, or prevent any disease. Metatide does not sell products intended for human consumption. Researchers are responsible for compliance with all applicable local, state, and federal regulations.